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Multiple sclerosis (MS) has long been considered an
immune based disease and some of the earliest attempts to
devise effective interventions were based on experience
gained from the treatment of systemic immune disorders
and included the use of less specific immunomodulating
agents and myeloablative treatments including autologous
hemopoietic stem cell transplantation (aHSCT). These
either proved ineffective or were not widely adopted
because of difficulties generating persuasive evidence for
long-term benefit and unacceptably high morbidity and
early mortality (in early studies, a mortality of 5 % or more
with bone marrow transplantation). In particular for
aHSCT it has proven difficult to generate informative
control groups, blind treatment groups and to separate the
effects of conditioning treatments prior to aHSCT and the
aHSCT itself. Despite this some centres have continued to
use aHSCT since 1995 in a small number of patients with
severe advanced disease resistant to standard interventions.
Because of these issues more targeted approaches to
modulating the immune system to treat MS has generally
been pursued over the last two decades. This has clearly
been successful and continues to gain momentum so that a
number of treatments are now available for different stages
and levels of disease aggression.
However, in this intervening period there have also been
parallel advances in aHSCT and in particular a reduction in
treatment associated mortality and morbidity. In addition
there has been an improved understanding of MS thera-
peutics with a trend towards earlier and more aggressive
interventions and an evolution in clinical trial design.
Recently, further pressure to re-examine the relevance of
aHSCT in MS has also been provided by a flurry of high
level media activity following the publication of a number
of open label studies and questions concerning the suit-
ability of this technology have become a common topic of
discussion between patients and clinicians within specialist
clinics.
aHSCT involves harvesting hemopoietic stem cells
before completely ablating (immunoablation) or partially
ablating the immune system with combinations of
chemotherapy, monoclonal antibodies and anti-thymocyte
globulin. The harvested stem cells are then reinfused, with
or without subtype selection, to reconstitute the immune
system. The process could be considered a partial or
complete ‘‘reprogramming’’ of the immune system. In this
month’s journal club we discuss three papers describing
aHSCT for the treatment of MS. The first paper describes a
case series of patients treated with nonmyeloablative
aHSCT. The second and third papers describe results from
phase 2 trials of myleoablative aHSCT.
Association of nonmyeloablative hemopoietic
stem cell transplantation with neurological
disability in patients with relapsing-remitting
multiple sclerosis
This paper describes a case series of 151 patients with MS
treated at a single US hospital. 22 (15 %) patients were
conditioned with cyclophosphamide and alemtuzumab,
with the remainder [129 (85 %)] receiving cyclophos-
phamide and anti-thymocyte globulin before autologous
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(81 %) had relapsing-remitting and 28 (19 %) had sec-
ondary progressive MS. Fifty five patients were treated on
the study protocol and met the following criteria: relapsing-
remitting MS, Extended Disability Status Scale (EDSS)
scores of between 2.0 and 6.0, received treatment with at
least 1 FDA approved drug [mostly beta-interferon but also
natalizumab (27 %) and fingolimod (8 %)], at least two
corticosteroid treated relapses within the last year or one
corticosteroid treated relapse and gadolinium enhancing
lesions on MRI. Ninety six patients were treated off the
study protocol on a compassionate basis for reasons
including having secondary progressive disease, an EDSS
score greater than 6.0 or particularly disabling disease. The
patients had regular EDSS, Multiple Sclerosis Functional
Composite (MSFC), Neurologic Rating Scale (NRS) and
short form 36 quality of life assessments as well as MRI
scans with gadolinium and were followed up for a median
of 2 years.
There were no deaths during the treatment. 14 (9 %)
patients had a post-transplant autoimmune adverse event
[immune-mediated thrombocytopenia (ITP), hypothy-
roidism or hyperthyroidism] with the proportion being
higher in the group receiving alemtuzumab compared with
anti-thymocyte globulin (9 % compared with 4 %).
The primary end point was change in EDSS score. The
mean EDSS score for the whole group improved signifi-
cantly after transplant, with 50 % and 64 % of patients
demonstrating an improvement in EDSS score of greater
than 1.0 point at 2 and 4 years, respectively. NRS and
MSFC scores also improved significantly after treatment.
80 % and 68 % of patients had no new relapses, gadolin-
ium enhancing lesions on MRI or increase in their EDSS
score (disease free survival) at 2 and 4 years, respectively.
89 % and 80 % of patients had no new relapses at 2 and
4 years, respectively. A subgroup analysis suggested no
benefit in patients with progressive disease not having
relapses before treatment.
Comment: This study was a case series and not a
trial and contained a heterogeneous mix of patients with
both relapsing and progressive disease (despite the
title). A significant proportion of patients (63 %) were
treated off study protocol on a compassionate basis and
the majority of patients had not received standard high
efficacy treatments. This together with the varying
conditioning regime including the use of alemtuzumab
exemplifies the difficulties in reaching firm conclusions
on the effect of aHSCT. On a positive note, there were
no deaths and a relatively low proportion of treatment
related complications when compared to other studies,
which is likely to be due to the use of a non-
myeloablative conditioning regime. EDSS scores were
presented as whole group averages, however, there was
a significant improvement in EDSS score for the
majority of patients and 80 % of patients achieved
disease free survival at 2 years.
Burt RK et al. (2015) JAMA 313(3):275–284.
High-dose immunosuppressive therapy
and autologous hemopoietic cell transplantation
for relapsing-remitting multiple sclerosis
(HALT-MS)
This paper reports an interim analysis of the HALT-MS
trial. HALT-MS is a single arm, multicentre, phase 2 trial
of immunoablation (using carmustine, etoposide, cytara-
bine, melphalan and anti-thymocyte globulin) followed by
autologous transplantation of CD34-selected stem cells.
Twenty five patients were treated who had: relapsing-
remitting MS, an EDSS score of between 3.0 and 5.5, and 2
or more clinical relapses in 18 months despite being on
treatment. The patients had a median EDSS score of 4.5
and had failed a median of 3 treatments at inclusion. Fol-
low-up included regular EDSS, MSFC and 29-item Mul-
tiple Sclerosis Impact Scale assessments as well as regular
MRI scans with gadolinium. The median length of follow-
up was 3.5 years.
One patient had a pulmonary embolus during the stem
cell mobilisation phase and did not proceed further with the
study. One patient died 2.5 years after treatment due to MS
progression and another patient died 3.5 years after treat-
ment due to worsening of asthma. Both of these patients
had met the end point of the trial before death having had
neurological progression and a relapse in the context of
aseptic meningitis, respectively. The authors report 130
grade 3 (severe) and 94 grade 4 (life-threatening or dis-
abling) toxic events, most of which were expected
cytopaenias or infections.
The primary end point was the time to treatment failure.
At 2 and 3 years, the overall event-free survivals (no pro-
gression in EDSS, clinical relapses or new gadolinium
enhancing lesions on MRI) probability, were 83 % and
78 % respectively. The EDSS score had improved from
baseline by a median of 0.5 points after 3 years.
Comment: These were the preliminary results from a
small, single-arm trial. The authors give detailed infor-
mation about the frequency of severe and life-threaten-
ing adverse effects that can be expected following
complete immune system ablation. However, the two
deaths described did not seem to be directly related to
treatment. The event-free survival probabilities are
impressive but comparable to previous phase II and III
studies of high efficacy treatments already available for
relapsing disease.
Nash RA et al. (2015) JAMA Neurol 72(2):159–169.
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Immunoablation and autologous hemopoietic stem
cell transplantation for aggressive multiple
sclerosis: a multicenter single-group phase 2 trial
This was a single arm, multicentre, phase 2 trial of
immunoablation (using cyclophosphamide, busulfan and
rabbit anti-thymocyte globulin) followed by autologous
transplantation of CD34-selected stem cells, across three
Canadian hospitals. Twenty four patients with aggressive
MS were included, 50 % had relapsing-remitting and 50 %
had secondary progressive disease. All patients had mul-
tiple early relapses, an EDSS score of at least 3.0 within
5 years of diagnosis and evidence of ongoing clinical dis-
ease activity despite at least 1 year of immunosuppressive
treatment (mostly beta-interferon). The patients had regular
EDSS and MSFC assessments as well as MRI scans with
gadolinium and were followed up for a median of
6.7 years.
One patient died of hepatic necrosis and sepsis 62 days
after transplantation and another patient required intensive
care admission before recovering fully. All 23 surviving
patients were free of clinical relapses and new gadolinium
enhancing lesions for the duration of follow-up (median of
6.7 years). 17 (70 %) patients had no further progression in
their EDSS scores after treatment and 8 (35 %) patients
had a sustained improvement in their EDSS scores 3 years
after treatment. Rates of brain atrophy were not signifi-
cantly different to those of healthy volunteers.
Comment: Although this was a small, single-arm trial, a
broad range of outcome measures including measures of
brain atrophy have produced some persuasive results over a
relatively long period of follow-up. All participants who
completed the trial had cessation of clinical relapses and no
new lesions on MRI. A significant proportion of partici-
pants had a functional improvement 3 years after
treatment, despite a high baseline level of disability and
half the participants having secondary progressive disease.
The level of treatment success in this study may have been
due to the relatively high doses of immunoblative
chemotherapy used and the selection of CD34 cells for
transplantation. However, the results need to be balanced
by the significant toxicity including a 4 % mortality rate.
Atkins HL et al. (2016) Lancet 388(10044):576–585.
Conclusion: Overall, the results of these studies offer
some encouragement for continuing investment in the role
of aHSCT in MS. However, there is an undeniably high
incidence of severe adverse events, including death, that
needs to balance against any benefit which must be sus-
tained over the longer term so that further follow-up will be
essential. In addition appropriate patient selection will be
key and it now seems clear that aHSCT is not effective in
progressive patients and the ethics of including this group
in future trials seem questionable. None of these studies
shed further light on the relative effect of conditioning
versus transplantation, which must be resolved before
wider use is considered. Finally, it would also be of value
to compare the efficacy of aHSCT directly against cur-
rently available high efficacy treatments despite the diffi-
culties in trial design this would generate.
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